Navigation Links
Repligen Reports Second Quarter Fiscal Year 2009 Financial Results
Date:11/6/2008

signation by the FDA, a process designed to facilitate the development and expedite the review of drugs that treat serious diseases and fill an unmet medical need. There are more than 300,000 procedures conducted in the United States and Europe each year that may benefit from enhancement with RG1068.

RG2417 for Bipolar Disorder

We have initiated a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. This is a multi-center, randomized, double-blind, placebo-controlled clinical trial in which approximately 150 patients with bipolar depression will receive either RG2417 or a placebo twice a day for eight weeks. This study is designed to assess the efficacy and safety of RG2417 on the symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression of Change in Bipolar Disorder scale (CGI-BP-C). This study is based on the positive results of a Phase 2a study in which 83 patients received either RG2417 or a placebo twice a day for six weeks. Over the six- week treatment period, the study demonstrated a statistically significant improvement in the symptoms of depression in the patients receiving RG2417 when compared to placebo on the MADRS (p=0.01) and the CGI-BP-C (p=0.04).

HDAC Inhibitors for Friedreich's Ataxia and Huntington's Disease

We are currently developing inhibitors of histone deacetylases (HDACs) which may have utility in treating progressive, inherited neurodegenerative diseases such as Friedreich's ataxia and Huntington's disease. We have identified several potential clinical candidates and are further characterizing these leads in animal models for their pharmacologic, toxicologic and pharmacodynamic profiles. Repligen announced receipt of a $1 million research grant from the Muscular Dystrophy Association and a $125,000 grant from the Friedreich's Ataxia Research Alliance and the National Ataxia Foundation. The grants
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
2. Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST
3. Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors
4. Repligen Announces Share Repurchase Program
5. Repligen Announces Conference Call to Update Orencia(R) Lawsuit
6. Repligen Elects Earl Henry, M.D. to the Board of Directors
7. Repligen to Present at Upcoming Healthcare Conferences Wednesday, November 28th and Wednesday, December 5th
8. Repligen Reports Second Quarter Fiscal Year 2008 Financial Results
9. Stereotaxis Reports Third Quarter 2008 Financial Results
10. Volcano Reports 40 Percent Growth in Quarterly Revenues
11. Dialysis Corporation of America Reports Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Texas (PRWEB) May 06, 2015 ... of the HIMSS EMR Adoption Model, the hospital ... improve patient engagement and automate processes. The leadership ... from paper-driven to electronic workflows, patient registration still ... copies of consents. With HIMSS Stage 7 attestation ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Corporate ... behalf of MEBC, an Alliance Award for excellence ... during FOCUS 2015, JDA’s annual user conference which ... retail and wholesale distribution sectors. This award recognizes ... are receiving services that advance their supply chain ...
(Date:5/6/2015)... 06, 2015 The Beryl Institute announces ... of Patient Experience Journal (PXJ), an international, open access, ... understanding and improving patient experience. The second volume of ... conversation globally, helps align the voices engaged and provides ... Published in association with The Beryl Institute, Volume 2, ...
(Date:5/6/2015)... Marketing Maven announces a ... sanitation and hygiene nonprofit by GuideStar’s Philanthropedia. , “WaterAid ... and it brings our agency great joy to work ... “The ongoing relationship between WaterAid and Marketing ... learn about and support the nonprofit as they aim ...
(Date:5/6/2015)... 06, 2015 Wolters Kluwer , ... and students, announced today that in a survey of ... use of the clinical decision support resource improves the ... of 2014, UpToDate users in more than 170 countries ... month, on average. In Germany alone, 95% of all ...
Breaking Medicine News(10 mins):Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 2Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 3Health News:MEBC Receives Award for Consulting Excellence in Retail 2Health News:Patient Experience Journal Releases Spring 2015 Issue 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 3Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3
... 500 Executive Driving Global Breast Cancer Leader,s Promise ... End Breast Cancer Forever, ATLANTA, Jan. 12 Hala ... the global leader in the fight to end breast,cancer forever, ... annual Trumpet Awards event in Atlanta with a ,High Heels ...
... Diseases than Ever ... ... childhood influenza and adolescent meningococcal,vaccinations are included in the 2008 Childhood ... Control and,Prevention (CDC), the American Academy of Pediatrics (AAP), and the,American ...
... NEW YORK, Jan. 11 The Substance Abuse ... from the National Survey on Drug Use and ... S. aged 12 to 25 have abused non-prescription,over-the- ... high at least once,in their lifetime. This announcement ...
... health care reform is too important, the stakes for, Californians ... ... changes., SACRAMENTO, Calif., Jan. 11 As the ... hammered out by Governor Arnold Schwarzenegger and Assembly,Speaker Fabian Nunez, the state,s ...
... genetic, biological causes could lead more to feel comfortable ... When people understand the genetics and biology of anorexia ... the eating disorder for their illness, says a University ... , "This is a potentially important finding because it ...
... diet and lifestyle are at root of reduced risk, , , FRIDAY, ... in your blood may reduce your risk of stroke, new research ... C in their blood had a 42 percent lower risk of ... which is in the January issue of The ...
Cached Medicine News:Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 3Health News:Health Groups Release 2008 Immunization Schedules 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse 3Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse 4Health News:Insurance Agents Call for State Senate to Improve California's Health Care Reform Compromise 2Health News:Science Could Erase Stigma of Anorexia 2Health News:Vitamin C May Play Role in Stroke Prevention 2Health News:Vitamin C May Play Role in Stroke Prevention 3
(Date:5/6/2015)... 2015 Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced that the ... community to review the clinical development strategy for ... on Friday, May 8, 2015. Topics will include ... planned clinical activities for AST-OPC1. ...
(Date:5/6/2015)... 2015 Delcath Systems, Inc. (NASDAQ: DCTH ... on oncology with an emphasis on the treatment of ... the three months ended March 31, 2015.  ... include: , Achieved quarterly product revenue of $0.44 ... the first quarter of 2014; , Activated a ...
(Date:5/6/2015)... Health (NYSE: CVS ) officially announced today that it will ... heavy fire damage during protests last week.  "As we ... the past week or so, our hearts turned from pain to ... CEO Larry Merlo . "Our purpose as a company is ... better way that we can fulfill that purpose than to reopen ...
Breaking Medicine Technology:Asterias Biotherapeutics to Host Investor Meeting to Review Clinical Development Strategy for AST-OPC1 in Spinal Cord Injury 2Asterias Biotherapeutics to Host Investor Meeting to Review Clinical Development Strategy for AST-OPC1 in Spinal Cord Injury 3Delcath Reports 2015 First Quarter Financial Results 2Delcath Reports 2015 First Quarter Financial Results 3Delcath Reports 2015 First Quarter Financial Results 4Delcath Reports 2015 First Quarter Financial Results 5Delcath Reports 2015 First Quarter Financial Results 6Delcath Reports 2015 First Quarter Financial Results 7Delcath Reports 2015 First Quarter Financial Results 8CVS Health Announces it Will Rebuild Baltimore CVS/pharmacy Locations 2
Microseal 'F' foil, seals plates for cold storage (or cycling >25l), disposable, pkg of 100...
Pkg qty: box of 2 bags pack of 25 (Pack = Zippered Bag)...
Transparent film for easy visual monitoring of samples...
... Biosystems has developed a comprehensive set ... using sequence detection systems (SDS) reagents ... and easy to follow. Many traditional ... and the thermal cycling protocol itself, ...
Medicine Products: